Business

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement ...

articleAspire Biopharma Holdings, Inc.July 30, 20254/company/aspire-biopharma-inc/news/aspire-biopharma-holdings-inc-announces-234500775
Aspire Biopharma Holdings, Inc. Announces CEO Transition

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO","length":69,"tagName":"p"},{"type":"text","content":"ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced that the Company's Board of Directors (Board) has appointed Kraig Higginson as interim Chief Executive Officer (CEO), effective July 24, 2025. Mr. Higginson serves as Chairman of the Board and previously served as CEO of Aspire for four years. Michael C. Howe has resigned as CEO and as a member of the Board. The Board thanks Mr. Howe for his contributions to the Company and plans to initiate a search for a permanent CEO.","length":662,"tagName":"p"},{"type":"text","content":""On behalf of the entire Board, I want to thank Michael for his contributions to the Company and wish him the very best in the future," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "I look forward to leading Aspire with the same level of commitment as if I were in the role permanently, with a goal of continuing to execute on maximizing the potential of Aspire's powerful and differentiated drug delivery platform. We are fortunate to have a capable leadership team, and we will continue to focus on positioning the business for long-term success."","length":593,"tagName":"p"},{"type":"text","content":"The Company also announced the resignations of Mr. Gary E. Stein and Ms. Barbara Sher from the Board, effective immediately. The Aspire Board is very grateful for Mr. Steins's and Ms. Sher's outstanding service as members of the Board and for all of the thoughtful insights and valuable contributions they provided during their tenures.","length":344,"tagName":"p"},{"type":"text","content":"In connection with this transition, the Board of Directors appointed Howard Doss, to serve as Director and Chairman of the Audit Committee of the Company, effective immediately.","length":177,"tagName":"p"},{"type":"text","content":"Mr. Doss, age 71, has served as the Chief Financial Officer of PowerUp from August 2023 until February 2025. He is a seasoned chief financial officer and accountant. He served as Chief Financial Officer of Kernel Group Holdings, Inc. In 2021, he ...

More updates from Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc.The CompanyChief Financial OfficerBarbara SherKraig HigginsonHoward DossAspire BiopharmaChairman of the BoardMichael C. HoweCompanyBoard of Directors